Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Transplantation. 2019 Jul;103(7):1338-1348. doi: 10.1097/TP.0000000000002704.
Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as advances in imaging modalities have allowed a direct window into the natural history of the disease. Innovation in diagnostic modalities has spurred the proliferation of prognostic tools and biomarkers. And in parallel, pharmacological advances have emerged that have helped ameliorate the disease's progressive course.
心脏移植后发生的同种异体移植物血管病仍然是影响心脏移植受者长期生存的主要限制因素。随着成像技术的进步,我们对其发病机制的认识也在不断发展,使我们能够直接了解疾病的自然病程。诊断方法的创新也促进了预后工具和生物标志物的大量涌现。与此同时,药理学的进步也有助于改善疾病的进行性病程。